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Resum. Les malalties complexes són causades per una com­
binació de factors genètics, ambientals i socioculturals, que 
interacciones entre si i amb el factor temps. Són molt comunes 
en la població i bona part també són cròniques, una combina­
ció que comporta alts costos d’atenció sanitària. Però també 
són malalties que es poden prevenir, fet que també té moltes 
implicacions importants per als sistemes sanitaris. Els biomar­
cadors ens permeten integrar les dades clíniques, bioquími­
ques i genètiques per a calcular millor el risc d’una malaltia. A 
més, en molts casos, també sabem com controlar els factors 
socioculturals que contribueixen a la malaltia, com ara l’adop­
ció d’una dieta i un estil de vida diferents. En aquest sentit, la 
medicina personalitzada convida els pacients a prendre acci­
ons clares per a millorar llur estat de salut, prevenir el desenvo­
lupament d’una malaltia o reduir­ne la gravetat. 
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Summary. Complex diseases are caused by a combination of 
genetic, environmental and sociocultural factors, interacting 
with one another and with the factor of time. They are very 
common among the population and most of them are also 
chronic, a combination that implies high healthcare costs. But 
they are also preventable, which likewise has many important 
implications for healthcare systems. Biomarkers allow us to in­
tegrate clinical, biochemical and genetic data to better calcu­
late the risk of disease. Furthermore, in many cases we also 
know how to control the sociocultural factors contributing to 
the disease, such as adopting different diet and lifestyle choic­
es. In this sense, personalised medicine allows and invites pa­
tients to take clear actions to improve their health status, pre­
vent the development or reduce the severity of a disease. 
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Complex diseases
If we talk about the relationship between genetics and socio­
cultural factors in determining the risk of developing a particu­
lar disease, what we are in fact talking about is complex dis­
eases, in which the relationship between genetics and 
sociocultural factor is well established. Thus, in complex dis­
eases, general socio­economic, cultural, and environmental 
conditions, such as agriculture, food production, education, 
work environment, unemployment, water and sanitation, 
healthcare services, and housing, interact with social and 
community networks, individual lifestyle factors, and a per­
son’s sex and age. According to several studies, the weight 
of both genetics and sociocultural factors in the risk of devel­
oping a complex disease is 40–60 % [X]. 
What are the characteristics of complex diseases? First of 
all, as their name states, they are complex, as several factors 
interact to promote these diseases in a particular person. An­
other characteristic of complex diseases is that they are very 
common among the population, and most of them are chronic 
diseases. The combination of common and chronic implies 
high healthcare costs. But, these complex diseases are also 
often preventable, which likewise has many important implica­
tions for healthcare systems. 
In complex diseases, genes and/or our sociocultural or en­
vironmental factors may predispose a person, or not, to a 
particular disease. Furthermore, these factors interact not 
only with each other but also with another important aspect, 
which is time. A clear and classic example of the time­related 
development of a complex disease is atherosclerosis. If we 
look at the timeline of atherosclerosis development, we see 
that endothelial dysfunction progresses, sometimes as long 
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as four decades from the initial lesion until the atherosclerotic 
lesion. During this period, lipid accumulation in the arteries 
(foam cells, fatty streaks, intermediate lesions, atheroma) is 
eventually followed by the formation of fibrous plaques and 
complicated lesions (Fig. 1). 
Accordingly, time is also a very important factor in the thera­
peutic equation, because it means that we have time to inter­
vene, in this case, to prevent the development of atherosclero­
sis. Another important point is that because of the combination 
of genetic and sociocultural factors, the disease process can 
be very fast or very slow. For example, some people with an 
adverse combination of genes and sociocultural factors devel­
op atherosclerosis and myocardial infarction by the age of for­
ty­five whereas those with a protective combination develop 
atherosclerosis very late in life or not at all. 
Although there might not be much we can do about the ge­
netic contribution, in many cases we do know how to control 
the sociocultural factors, which is thus where our efforts should 
be concentrated. Sociocultural factors affect our exposure and 
vulnerability to disease because they include risk­taking behav­
iours. They are also important in gauging the effectiveness of 
health promotion efforts, including the access to, availability of, 
and quality of healthcare, and in the perceptions of and re­
sponses to health problems. 
But, has acting on sociocultural factors ever proved to be 
efficacious? The answer is yes. Studies of the percentage de­
crease in deaths from coronary heart disease (CHD) attributed 
to treatment and to risk factor changes in different countries [1] 
have shown that, in most cases, altering sociocultural factors is 
highly relevant as it is associated with a two­fold higher reduc­
tion in CHD than obtained by treatment. The goal is to integrate 
sociocultural, biochemical, clinical and genetic factors in an al­
gorithm that could quickly provide an estimate of the risk to 
develop a disease, and therefore identify preventative meas­
ures or therapeutic objectives for a particular person. 
Throughout the 2012 EPTA meeting, it was often stated 
that we still know very little about our genes and the genome. 
While this is true, the following practical example shows that, 
despite these gaps in our knowledge, we can learn much 
from the information currently available to us. During a visit to 
Japan, I carried out a small experiment that, since I do not 
know how to read Japanese, would at least allow me to iden­
tify the Japanese characters for ‘exit’ and for ‘toilet.’ Rela­
tively quickly, I was able to clearly establish a relationship be­
tween some particular characters and the exit and other 
particular characters and the toilet, without any problem and 
with a success rate of 100%. 
The same type of experiment can be carried out with bi­
omarkers. Thus, even though we do not understand the rela­
tionship between certain biomarkers and either disease or 
sociocultural factors, it does not prevent us from establishing 
a clear association between a particular marker and a particu­
lar disease/sociocultural factor and then validate it. Having 
done so, we will find that the knowledge, like the distinction 
between the toilet and the exit, is highly useful. And, analo­
gous to gradually acquiring competence in a foreign lan­
guage, as our understanding of the genome expands, we will 
eventually understand the reasons why those particular bi­
omarkers are associated with a particular disease. But for the 
time being, in order to identify risk, we do not need to under­
stand the whole story. Rather, we can use the aforemen­
tioned algorithms that combine different biomarker measure­
ments to determine the risk that the individual in question will 
develop the disease under study. 
Several speakers at this conference also mentioned the Per­
sonalized Medicine Coalition (PMC), which represents innova­
tors, academics, industry, and patient and provider communi­
ties in the advancement and adoption of the concepts and 
products of personalised medicine. In the view of this organiza­
tion, the future might be as follows:
An email alerts the physician about a new study demon­
strating a connection between multiple rare mutations and the 
likelihood of developing type 2 diabetes. The physician then 
conducts a quick search of her patient database and finds 
some patients who are at risk in that according to their medical 
records they have pre­diabetic symptoms. The physician then 
sets up appointments with these patients to consider proactive 
treatment with drugs that can prevent disease onset. Those 
patients at risk but without pre­diabetic symptoms are sent a 
strong reminder and advice on diet and lifestyle choices they 
can adopt to avoid disease occurrence. 
While for the PMC this is a view of the future, there are sev­
eral current examples showing that this future is now. One 
thing that we should keep in mind, and which is illustrated by 
the PMC’s vision, is that genetic and other personalised med­
icine tests should be channelled through physicians, and not 
offered openly to the general population. This can be regulat­
Fig 1. Stages of endothelial dysfunction in atherosclerosis. Source: 
Wikimedia Commons.
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ed in the same way that the acquisition of antibiotics is regu­
lated, by the requirement for a doctor’s prescription. It is im­
portant to remember that genetic tests provide information 
that can be very useful, but it must be used specifically and 
the results evaluated by those with the skills to do so. 
The case of Cardio inCode
To illustrate this point, I offer as an example one of the services 
that Gendiag (www.gendiag.com), the biotechnology compa­
ny I work for, has developed. Cardio inCode® is a personalised 
medicine product that is already available to physicians. It is a 
cardiovascular risk assessment DNA­chip that has been de­
signed to predict low­intermediate cardiovascular risk. By iden­
tifying gene polymorphisms related to cardiovascular disease 
phenotypes and their markers in 111 gene polymorphisms, it 
assesses an individual’s risk of suffering from a cardiovascular 
event (angina, myocardial infarction, stroke, or peripheral arte­
riopathy) in the next 10 years. To calculate this risk, Cardio in­
Code incorporates clinical, biochemical, and genetic data into 
a validated risk algorithm. It also assesses the genetic predis­
position to develop the classical cardiovascular risk factors. Fi­
nally, for the physician to provide advice to his or her patient, 
Cardio inCode’s report also considers the sociocultural factors 
affecting that particular patient. 
For all platforms in personalised medicine, it is important to 
obtain both clinical validation and analytical validation. Cardio 
inCode has been validated clinically in several studies. Specifi­
cally, clinical validation was aimed at establishing the associa­
tion of disease biomarkers with the risk of the disease, and 
whether the approach used by Cardio inCode to calculate car­
diovascular risk improves the predictive capability of the risk 
equations currently in use. The linear relationship between as­
sociated risk and the number of risk alleles was confirmed in 
two different large cohorts during clinical trials carried out by 
the Cardiovascular Group of the Municipal Institute for Medical 
Research of the Hospital del Mar and Gendiag [3,4]. 
To validate the biomarkers, the criteria of the American 
Heart Association for the evaluation of novel markers of cardio­
vascular risk were followed [2]:
1.  Proof of concept: Do novel marker levels differ between 
subjects with and without outcome?
2.  Prospective validation: Does the novel marker predict the 
development of future outcomes in a prospective cohort 
or nested case­cohort/case cohort study?
3.  Incremental value: Does the novel marker add predictive 
information to established, standard risk markers?
4.  Clinical utility: Does the novel risk marker change predict­
ed risk sufficiently to change recommended therapy?
5.  Clinical outcome: Does the use of the novel risk marker 
improve clinical outcomes, especially when tested in a 
randomised clinical trial?
6.  Cost­effectiveness: Does use of the marker improve clin­
ical outcomes sufficiently to justify the additional costs of 
testing and treatment? 
The association of genetic markers with the disease is in 
the same range as that of currently used risk factors, such as 
cholesterol and high blood pressure, whose association with 
cardiovascular disease is well studied. From the results of 
Gendiag’s studies, it was concluded that Cardio inCode pro­
vides more accurate information than obtained from the clas­
sical risk equations [3,4]. This allows for more effective pre­
ventive actions, a better definition of therapeutic objectives, 
and their improved achievement. 
Personalised medicine allows and invites patients to take 
clear actions to improve their health status. Figure 2 shows an 
example of some of the sections of the report we provide to 
patients. It allows us to inform a patient about the risk of de­
veloping coronary heart disease (CHD) based on his or her 
genetic profile genes and relevant sociocultural factors, but 
also to teach the patient how, by following certain actions, the 
risk of cardiovascular disease can be very significantly re­
duced. Thus, personalised medicine allows the physician to 
invite the patient to collaborate in reducing disease risk. 
A few decades ago, when we talked about cholesterol as a 
risk factor, we meant total cholesterol. But we now know that 
cholesterol is made up of different fractions, and that higher 
serum concentrations of LDL particles (low­density lipopro­
teins) and lower serum concentrations of functional HDL parti­
cles (high­density lipoproteins) are strongly associated with 
cardiovascular disease, because they promote atherosclero­
sis. By measuring cholesterol in blood and identifying the differ­
ences between LDL and HDL and their relationship to CHD, we 
have been able to develop more appropriate drugs for the pre­
vention and treatment of atherosclerosis and CHD. 
In personalised medicine, a commonly voiced concern is 
how insurance companies will use the information provided 
by a person’s sequenced genome. But we forget that risk 
factors can be used in the same way. Should we be as con­
cerned about our cholesterol measurements as we are about 
our genes? Cholesterol is a marker of risk: high serum choles­
terol implies a higher risk of developing CHD. But most of us 
do not object to providing insurance companies with our cho­
lesterol data. Yet the ethical concerns are essentially the 
same for cholesterol levels as for genetic markers. Further­
more, today, we do not have any problem in analyzing a per­
son’s cholesterol level, but in the early 1950s, when the 
Framingham Heart Study (www.framinghamheartstudy.
org)—a long­term ongoing cardiovascular study on the resi­
dents of Framingham, Massachusetts—began to evaluate 
these cohorts, they too were measuring several factors 
whose full implications they could not yet understand. This is 
currently the case for genetic information, which we can rela­
tively easily collect but only scarcely interpret.
Insights gained from experience
I would like to share some thoughts based on our experience 
in the development of personalised medicine products. First, 
with the aid of biomarkers—although we still do not under­
stand how they work—we can integrate clinical, biochemical, 
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genetic, and lifestyle data to better calculate disease risk. 
With improved estimates, more efficacious therapeutic and 
preventative objectives can be established and achieved. We 
will thus be better able to prevent disease development and 
to reduce disease severity. 
Second, other uses of personalised medicine are also possi­
ble, such as early diagnosis, prognosis, selection of best treat­
ment, and patient follow­up. The field of personalised medicine 
is just beginning, so our capabilities in terms of prediction, diag­
nosis, and prognosis are limited. But as knowledge, technologi­
cal development, and experience accumulate, so will our aware­
ness of the potential of personalised medicine. Figure 3 shows 
schematically how the individualised detection of genetic vari­
ants can help us predict disease predisposition as well as its use 
in early diagnosis and prognosis. Ultimately, we will become 
more efficient in prevention and treatment, thus increasing pa­
tients’ quality of life and reducing health costs. 
Third, it is interesting to consider that the technology re­
quired for personalised medicine is in continuous develop­
ment. Nowadays, there is intense competition between com­
panies but also difficulties in developing and bringing to 
market in vitro diagnostics (IVD) products. Well developed 
laboratory developed tests (LDTs) should be admissible. In 
the end, there will most likely be two main, complementary 
products: point of care (POC) and next generation sequenc­
ing (NGS). But in my opinion, from a legislative point of view, 
NGS should become the gold standard. 
Fourth, genetic tests should be used in clinical practice and 
they should be reimbursed, provided that the test has clinical 
and analytical validation and has been subject to rigorous cost­
efficiency studies. Educational programs on personalised med­
icine should be initiated at all levels: aimed at the public, physi­
cians, and politicians. In addition, cohort studies should be 
established and promoted in different countries. We have to be 
able to include samples and clinical data from different popula­
tions in order to better validate personalised medicine prod­
ucts, and to do so faster. 
Finally, there is the need for the proper allocation of resourc­
es. In Europe, we have been very good at providing funding for 
basic research, conscious that it generates knowledge, wealth 
in the form of patents, and the overall development of society. 
But we have also started funding translational medicine, as it 
Fig. 2. (A) Results from genetic factors associated with 
cardiovascular risk. Probability of coronary event in the 
next 10 years based on REGIOR function. (B) Results 
from genetic markers associated with pathophysiologi­
cal pathways.
Fig. 3. Pioneering services in personalised medicine.
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facilitates the applicability of knowledge, increases the value of 
knowledge, and rewards public investments in R&D, in terms 
of small, medium, and large enterprises, employment, and a 
better public health system. The latter depends on adequate 
funding for the application to society of the products we have 
developed. It does not make sense to fund basic research and 
translational medicine if in the end we do not benefit, economi­
cally or in terms of improved health, from our investments. Re­
sources set aside for personalised medicine applications will 
increase the overall efficiency of the system, provide patients 
with better treatment, improve the quality of life of the popula­
tion, reduce the wasteful exposure of patients to ineffective 
treatments, reduce treatment side effects, delay the develop­
ment of chronic diseases, emphasise prevention over treat­
ment, and provide resources to stakeholders in the value chain. 
To achieve these goals requires fairly distributed resources, 
both from funding agencies, proving funds for clinical analysis 
of the new personalised medicine tools, and from governmen­
tal bodies, to finance the purchase of these technologies so 
that they become adopted by the health system. 
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